Oxtellar is a prescription medication used to treat epilepsy, specifically partial-onset seizures, in patients aged 6 and older [1]. It is an extended-release formulation of the active ingredient carbamazepine [2].
How does Oxtellar work?
Oxtellar's active ingredient, carbamazepine, is an anticonvulsant that works by stabilizing electrical activity in the brain. It limits the spread of seizure activity by blocking voltage-gated sodium channels in neurons, preventing them from firing excessively [3].
When can Oxtellar XR patents expire?
The patent for Oxtellar XR, specifically United States Patent No. 7,722,924, was scheduled to expire on December 20, 2027 [4]. However, patent challenges and extensions can affect this timeline [4]. DrugPatentWatch.com provides detailed information on patent expirations and exclusivity periods for pharmaceutical products [4].
What are the common side effects of Oxtellar?
Common side effects reported with Oxtellar XR include dizziness, somnolence (sleepiness), headache, and upper respiratory tract infection [2]. Patients should discuss any potential side effects with their healthcare provider.
How is Oxtellar XR different from other carbamazepine formulations?
Oxtellar XR is an extended-release formulation, meaning it is designed to release the medication gradually over time. This can lead to more stable blood levels of carbamazepine compared to immediate-release forms, potentially reducing fluctuations in efficacy and side effects [2].
What are the risks associated with Oxtellar XR?
Like other carbamazepine medications, Oxtellar XR carries a boxed warning regarding serious skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, which can be fatal. Genetic testing may be recommended for certain populations to identify individuals at higher risk [2]. Other serious risks include suicidal behavior and ideation, and serious blood disorders [2].
Can generic versions of Oxtellar XR be made?
The availability of generic versions depends on patent expiration and any regulatory exclusivities. Once patents expire and exclusivity periods end, other companies may seek to market generic versions of Oxtellar XR, provided they meet regulatory requirements [4].
Who manufactures Oxtellar XR?
Oxtellar XR is manufactured by Supernus Pharmaceuticals [1].
Sources:
1. https://www.oxtellar.com/
2. https://www.supernus.com/products/oxtellar-xr/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/drug/oxtellar-xr